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During the 2009/10 influenza A(H1N1)pdm09 pan-
demic, the five Nordic countries adopted different 
approaches to pandemic vaccination. We compared 
pandemic vaccination strategies and severe influenza 
outcomes, in seasons 2009/10 and 2010/11 in these 
countries with similar influenza surveillance systems. 
We calculated the cumulative pandemic vaccination 
coverage in 2009/10 and cumulative incidence rates of 
laboratory confirmed A(H1N1)pdm09 infections, inten-
sive care unit (ICU) admissions and deaths in 2009/10 
and 2010/11. We estimated incidence risk ratios (IRR) 
in a Poisson regression model to compare those indi-
cators between Denmark and the other countries. The 
vaccination coverage was lower in Denmark (6.1%) 
compared with Finland (48.2%), Iceland (44.1%), 
Norway (41.3%) and Sweden (60.0%). In 2009/10 
Denmark had a similar cumulative incidence of A(H1N1)
pdm09 ICU admissions and deaths compared with the 
other countries. In 2010/11 Denmark had a signifi-
cantly higher cumulative incidence of A(H1N1)pdm09 
ICU admissions (IRR: 2.4; 95% confidence interval 
(CI): 1.9–3.0) and deaths (IRR: 8.3; 95% CI: 5.1–13.5). 
Compared with Denmark, the other countries had 
higher pandemic vaccination coverage and experi-
enced less A(H1N1)pdm09-related severe outcomes 
in 2010/11. Pandemic vaccination may have had an 
impact on severe influenza outcomes in the post-pan-
demic season. Surveillance of severe outcomes may 
be used to compare the impact of influenza between 
seasons and support different vaccination strategies.
Background
In 2009, the World Health Organization recommended 
adjuvanted vaccines in response to the A(H1N1)pdm09 
pandemic [1]. The five Nordic countries (Denmark, 
Finland, Iceland, Norway and Sweden) all used the 
monovalent AS03-adjuvanted pandemic influenza vac-
cine Pandemrix [2].
Several studies have estimated the effectiveness of the 
pandemic vaccine in preventing A(H1N1)pdm09 during 
the pandemic [3-7]. In addition, others have shown an 
effect against influenza A(H1N1)pdm09 in the post-
pandemic season as well as persistence of antibodies 
in children at sub-national or national level [8-10]. It is 
therefore possible that a high pandemic vaccination 
coverage in a population would affect the distribution 
of circulating influenza subtypes and disease severity 
for a longer period after a pandemic. We are not aware 
of any studies that assessed how different pandemic 
vaccination strategies may have affected the influenza 
type/subtype distribution and the epidemiology of 
severe influenza in the post-pandemic season.
The five Nordic countries are comparable with regards 
to demography [11], universal and equal access to the 
healthcare system [12], and healthcare practices [13]. 
They also had similar surveillance systems during 
the pandemic [14-18]. Furthermore, all Nordic coun-
tries established or strengthened their surveillance of 
severe influenza cases through reporting of influenza 
2 www.eurosurveillance.org
Figure 1
Cumulative pandemic vaccination coverage and laboratory-confirmed influenza A(H1N1)pdm09, influenza B and A(H3N2) 
cases by week, influenza seasons 2009/10 and 2010/11, Denmark, Finland, Iceland, Norway and Sweden
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A(H1N1)pdm09-related intensive care unit (ICU) admis-
sions and deaths in the 2009/10 and 2010/11 influenza 
seasons [14-19].
The objective of this study was to compare the five 
Nordic countries in terms of circulating influenza types/
subtypes and severe outcomes of influenza in the sea-
sons 2009/10 and 2010/11 in relation to the pandemic 
vaccination coverage and the timing of vaccination.
Methods
Study design and period
We conducted an ecological study where we retrospec-
tively compared aggregated data from two consecu-
tive influenza seasons: the pandemic season 2009/10 
(week 17 2009 – week 17 2010) and the post-pandemic 
season 2010/11 (week 40 2010 – week 20 2011) in the 
five Nordic countries.
Data collection
The national public health institutes of the five coun-
tries provided information about the recommendations 
for (i) pandemic vaccination such as target groups, 
beginning of vaccination campaigns and number 
of doses indicated, and (ii) virological sampling of 
patients with suspected influenza i.e. target groups 
and sampling protocols.
Each of the countries uses national unique personal 
identification numbers which enables the linkage 
of different national health registers but only aggre-
gated data were provided for the current study. The 
public health institutes provided data on laboratory-
confirmed influenza cases by type/subtype, influenza 
A(H1N1)pdm09-related ICU admissions, influenza-
related deaths, and the percentage of samples that 
tested positive for influenza from laboratories as well 
as the number of persons vaccinated. These numerator 
data were stratified by week of the influenza season. 
We obtained population denominators from Eurostat 
[11].
Definitions
The weekly and cumulative pandemic vaccination cov-
erages were calculated based on the individual regis-
tration of vaccinated individuals from each country by 
dividing the number of vaccinated individuals by the 
country population.
Notification of confirmed influenza A(H1N1)pdm09 
cases was mandatory in Finland, Iceland, Norway 
and Sweden [15,16,20]. In Denmark, notification was 
only mandatory in the 2009/10 season [17]. In sea-
son 2010/11, information on laboratory-confirmed 
cases was obtained from a newly established national 
database comprising all influenza test results [21]. 
Therefore, all laboratories in each of the Nordic coun-
tries were included in the reporting. The weekly and 
cumulative incidences of laboratory-confirmed influ-
enza A(H1N1)pdm09, A(H3N2) and influenza B cases 
were calculated by dividing the number of cases by 
100,000 country population for each season.
We defined severe outcomes of influenza A(H1N1)
pdm09 as influenza-related ICU admissions and 
deaths. During the pandemic, the surveillance of the 
A(H1N1)pdm09 cases included all ICUs in each of the 
five Nordic countries. The testing recommendations at 
hospital level were to swab all patients hospitalised 
with influenza-like illness symptoms or lower airway 
infections during the pandemic [22-24]. The A(H1N1)
pdm09 testing recommendations did not change during 
the 2010/11 season [25,26]. The cumulative incidences 
of influenza-related ICU admissions were calculated 
by dividing the number of patients admitted to the 
ICUs and diagnosed with influenza A(H1N1)pdm09 by 
100,000 country population for each season.
The number of influenza-related deaths was identified 
by obtaining information from the civil registry on date 
of death among the A(H1N1)pdm09 confirmed cases in 
Denmark, Finland and Sweden. Deaths that occurred 
within 30 days after the last influenza positive sample 
were considered. Each case was then reviewed and 
validated by national medical officers. In Iceland and 
Figure 2
Influenza A(H1N1)pdm09 and influenza B distribution 
by age group and country, Denmark, Finland, Iceland, 
Norway and Sweden, influenza seasons 2009/10 and 
2010/11
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Norway, a case-based reporting of all deaths associ-
ated with A(H1N1)pdm09 was in place from hospitals 
and healthcare facilities. The influenza-related mortal-
ity was calculated by dividing the number of influenza 
confirmed deaths by 100,000 country population for 
each season.
Data analysis
The pandemic vaccination coverage during the pan-
demic season was compared between the five 
countries.
In each influenza season, we compared the country 
incidence of laboratory-confirmed influenza by type/
subtype, A(H1N1)pdm09-related ICU-admissions and 
the A(H1N1)pdm09-related mortality. These indicators 
were also compared by age groups.
A Poisson regression model was used to compare the 
indicators between the Nordic countries for each influ-
enza season. We estimated the incidence risk ratio 
(IRR) and corresponding 95% confidence intervals 
(CI) for Denmark vs the other four countries, using the 
other countries as a reference. The statistical analysis 
was carried out using Stata 12 software.
Ethical considerations
The study only included aggregated surveillance 
data without personal identifiers. Therefore, no ethi-
cal approval was needed according to each country’s 
national regulations.
Results
Vaccination recommendations and coverage 
during the pandemic
In 2009, all countries recommended pandemic vac-
cination for healthcare workers, pregnant women and 
individuals aged six months or more with one or more 
chronic medical condition which increased the risk for 
influenza-related complications, from week 38 to 45 
(Table 1). In addition, Finland, Iceland, Norway and 
Sweden but not Denmark, recommended vaccination to 
the whole population aged six months of age or more 
from week 43 to 48.
Finland, Iceland and Norway recommended one vac-
cine dose for individuals aged 10 years or more. 
Sweden and Denmark started by recommending two 
doses and changed to one dose in week 46 and 49 
of 2009, respectively, for individuals aged above 10 
years old with a functioning immune system. Denmark, 
Iceland, Norway and Sweden recommended two doses 
for children below 10 years of age, while Finland rec-
ommended only one dose in this age group. Norway 
changed the recommendation to one dose in the same 
age group in week 51.
The Nordic countries started to administer the vac-
cine in September in Finland and in October 2009 in 
Denmark, Iceland, Norway and Sweden. The cumulative 
coverage of administered vaccines by the end of the 
pandemic was significantly lower in Denmark, 6.1%, 
compared with Finland, 48.2%, Iceland 44.1%, Norway 
41.3% and Sweden 60.0%. The percentage of vacci-
nated children below five years of age in Denmark was 
0.3%, in Finland 73%, in Iceland 43% and in Norway 
47%; data for Sweden was not available. The percent-
age of vaccinated population above 65 years of age in 
Denmark was 18%, compared with 49% in Finland, 59% 
in Iceland and 53% in Norway. In the 2010/11 season, 
the trivalent seasonal influenza vaccine (TIV) included 
A(H1N1)pdm09 as one of the three viruses, and this 
vaccine type was used in all five countries; Pandemrix 
was not in use during this season.
Table 1
Timing of recommendations of pandemic vaccination to target groups in Denmark, Finland, Iceland, Norway and Sweden, 
during the 2009/10 influenza A(H1N1)pdm09 pandemic
Country
Target groups recommended by week
Underlying conditionsa Healthcare workers and key community professionsb Pregnant women
Healthy population ≥ 6 
months of age
Denmark Week 43:  <  65 years of age Week 49: ≥  65 years of age Week 43
Week 45: 2nd and 3rd 
trimester Not recommended
Finland Week 45 Week 43 Week 44 Week 46: 6–35 months  Week 47: 3–24 years
Iceland Week 45 Week 42–43 Week 45 Week 48
Norway Week 38 Week 38 Week 38 Week 43
Sweden Week 42 Week 42 Week 42 Week 44–46c
a The countries included one or more of the following: pulmonary diseases, cardiovascular diseases, haemoglobinopathies, diabetes type 1 
or 2, congenital or acquired immune deficiencies, neuromuscular conditions, chronic liver or renal failure, other diagnoses which pose a 
serious health risk in conjunction with influenza.
b The countries included one or more of the following: police, firemen, firefighters, etc.
c According to regional planning.
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Incidence of laboratory-confirmed influenza 
and recommendations for testing
The weekly incidence of reported laboratory confirmed 
A(H1N1)pdm09 cases peaked in week 42 of 2009 in 
Iceland, week 45 in Norway, week 46 in Denmark and 
Finland and week 47 in Sweden. At the peak in each 
country, the cumulative pandemic vaccine coverage 
was below 10% for all countries except Sweden, where 
it was 30% (Figure 1).
During the pandemic, the influenza A(H1N1)pdm09 
virus was predominant among laboratory-confirmed 
influenza cases compared with influenza B and A(H3N2) 
viruses in the five Nordic countries. In Finland there 
was only information on A(H1N1)pdm09, but not on 
other subtypes of influenza A (Figure 1). In the 2010/11 
season, influenza B was predominant in Finland, 
Iceland, Norway and Sweden, contrary to Denmark 
where A(H1N1)pdm09 was predominant (Figure 1).
In 2009/10, the incidence of laboratory-confirmed 
A(H1N1)pdm09 influenza was significantly lower in 
Denmark compared with the other four Nordic coun-
tries (IRR: 0.6; 95% CI: 0.6–0.6; p value < 0.001) (Table 
2, 3). In 2010/11, the cumulative incidence of A(H1N1) 
pdm09 influenza was lower in all countries compared 
with 2009/10 (Table 2). In contrast to the previous sea-
son, it was significantly higher in Denmark than in the 
other four Nordic countries (IRR: 1.8; 95% CI: 1.7–1.9; p 
value < 0.001) (Table 2, 3).
Recommended target groups for testing were similar 
in the five countries. The swabbing of cases and their 
contacts started in week 17 in Sweden, week 18 in 
Denmark, Finland and Norway and week 21 in Iceland. 
The swabbing recommendations changed to only risk 
group patients or close contacts of confirmed cases in 
all countries from week 29 in Denmark and Sweden, 
week 30 in Norway, week 31 in Finland and week 33 in 
Iceland (Table 4).
The number of positive A(H1N1)pdm09 cases among the 
total tested was available in Iceland (19.6%), Norway 
(21.4%) and Sweden (23.6%) in the 2009/10 season. In 
season 2010/11, the percentage of positives decreased 
in the three countries and was 3.5% in Iceland, 6.4% in 
Norway and 6.2% in Sweden.
Influenza A(H1N1)pdm09-related ICU 
admissions and mortality
During the pandemic season, the incidence of A(H1N1)
pdm09-related ICU admissions was statistically signifi-
cantly lower in Denmark and Sweden than in Finland, 
Iceland and Norway (Table 2). In the 2010/11 season, 
the incidence was lower than during the pandemic in 
all countries except for Denmark. In 2010/11, Denmark 
had a higher incidence of A(H1N1)pdm09-related ICU 
admissions (IRR: 2.4; 95% CI: 1.9–3.0; p value < 0.001) 
compared with the other Nordic countries (Table 2,3).
In the 2009/10 season, there were no statistically sig-
nificant differences between the influenza A(H1N1)
pdm09-related mortality in the five countries (Table 
2,3). In 2010/11, the influenza A(H1N1)pdm09-related 
mortality was significantly higher in Denmark compared 
Table 2
Rates of laboratory-confirmed influenza A(H1N1)pdm09 and ICU admissions and deaths related to influenza A(H1N1)
pdm09, influenza seasons 2009/10 and 2010/11, Denmark, Finland, Iceland, Norway and Sweden
Country
Laboratory-confirmed A(H1N1)pdm09 A(H1N1)pdm09-related ICU admissions A(H1N1)pdm09-related deaths
Season 2009/10 Season 2010/11 Season 2009/10 Season 2010/11 Season 2009/10 Season 2010/11
n
Incidence 
n/100,000 
(95%CI)
n
Incidence 
n/100,000 
(95% CI)
n
Incidence 
n/100,000 
(95%CI)
n
Incidence 
n/100,000 
(95%CI)
n
Incidence 
n/100,000 
(95%CI)
n
Incidence 
n/100,000 
(95%CI)
Denmark 5,497
99.3 
(96.7–
101.9)
1,671
30.2 
(28.7–
31.6)
93 1.6 (1.3–2.0) 106 1.9 (1.5–2.3) 30 0.5 (0.3–0.7) 53
0.9 
(0.7–1.2)
Finland 7,666
143.2 
(140.0–
146.4)
877 16.3 (15.3–17.5) 133
2.4 
(2.0–2.9) 52 0.9 (0.7–1.2) 44 0.8 (0.6–0.1) 13
0.2 
(0.1–0.4)
Iceland 696
219.1 
(203.4–
236.0)
24 7.5 (5.0–11.3) 17
5.3 
(3.3–8.6) 1 0.3 (0.04–2.2) 2 0.6 (0.1–2.5) 0 0
Norway 13,707
282.1 
(277.4–
286.9)
1,365
28.0 
(26.6–
29.6)
147 3.0 (2.5–3.5) 43 0.8 (0.6–1.1) 32 0.6 (0.4–0.9) 1
0.02 
(0.00–0.1)
Sweden 11,002
117.7 
(115.6–
120.0)
1,125 12.0 (11.3–12.7) 116
1.2 
(1.0–1.4) 64 0.6 (0.5–0.8) 36 0.3 (0.2–0.5) 9
0.09 
(0.05–0.2)
p value < 0.001 p value < 0.001 p value < 0.001 p value < 0.001 p value < 0.05 p value < 0.001
n: number; CI: confidence interval; ICU: intensive care unit.
p values were calculated through Poisson regression.
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with the other countries (IRR: 8.3; 95% CI: 5.1–13.5; p 
value < 0.001).
Discussion
There was a wide variation in pandemic vaccination 
strategies during the pandemic in Europe, and the influ-
enza A(H1N1)pdm09 pandemic vaccination coverage 
previously reported for the entire population ranged 
from 0.5% to 59% across European countries [27]. We 
evaluated how the pandemic and the post-pandemic 
influenza seasons progressed in the Nordic countries 
and present the results in light of the different vacci-
nation strategies used. A similar approach would have 
been difficult at the European level due to the heteroge-
neous populations, different healthcare and different 
influenza surveillance systems. The Nordic countries 
are comparable regarding these factors which gave 
us a unique opportunity to study differences in severe 
outcomes of influenza A(H1N1)pdm09 in the pandemic 
and post-pandemic seasons in relation to the vaccina-
tion coverage during the pandemic.
The pandemic vaccination coverage was 6% in Denmark 
where vaccination was only recommended for at-risk 
groups, compared with 41 to 60% in the other four 
Nordic countries where vaccination was recommended 
for the whole population. The timeliness of vaccination 
varied by a few weeks with Sweden having the high-
est proportion of the population vaccinated before the 
epidemic peak.
All Nordic countries reported that the most frequent 
influenza type during the pandemic was A(H1N1)
pdm09, with Denmark and Sweden having the lowest 
rates of laboratory-confirmed A(H1N1)pdm09 cases 
overall and cases admitted to ICU. However, in the fol-
lowing influenza season, 2010/11, A(H1N1)pdm09 dom-
inated in Denmark, whereas influenza type B was the 
predominant virus in the other four Nordic countries. 
Furthermore, in the 2010/11 season, Denmark experi-
enced a higher incidence of A(H1N1)pdm09-related ICU 
admissions and deaths than the other Nordic countries.
The higher incidence of laboratory-confirmed influ-
enza A(H1N1)pdm09 cases and related ICU admissions 
and deaths in Denmark in the 2010/11 season could 
be due to less natural or vaccine-induced immunity in 
the population in the post-pandemic season compared 
with the other countries. Studies on the burden of the 
pandemic influenza in Denmark have estimated a clini-
cal attack rate of 5% [28] which is indeed lower than 
the clinical attack rate of 30% estimated in Norway 
[29]. However, the latter number was obtained by using 
a different method [29]. Clinical attack rates were not 
available for the other Nordic countries.
Other European countries have reported findings simi-
lar to those observed in Denmark. In 2010/11, the United 
Kingdom (UK) reported a higher level of daily number 
of confirmed and suspected influenza cases in critical 
care and a higher number of deaths compared with the 
2009/10 pandemic season [30,31]. Pandemic vaccina-
tion coverage was estimated to be 15% for the general 
population in Scotland [32]. The coverage was 35% for 
the risk groups in the UK where it provided some pro-
tection against laboratory-confirmed influenza A(H1N1)
Table 3
Rates of laboratory-confirmed influenza A(H1N1)pdm09 and influenza B cases, ICU admissions and mortality due 
to influenza A(H1N1)pdm09 in Denmark compared with the other countries (Finland, Iceland, Norway and Sweden), 
influenza seasons 2009/10 and 2010/11
Rates of laboratory-
confirmed influenza 
A(H1N1)pdm09 and 
influenza B cases, 
A(H1N1)pdm09 ICU 
admissions and 
mortality
Season 2009/10 Season 2010/11
Denmark Other countriesa Denmark Other countriesa
Incidence 
n/100,000
95% 
CI
IRRb 
(95% 
CI)
p value Incidence n/100,000 95% CI
Incidence
/100,000
95% 
CI IRR
b p value Incidence /100,000
95% 
CI
A(H1N1)pdm09 99.3 96.7–102.0
0.6 
(0.6–
0.6)
p < 0.001 166.4 164.7–168.2 30.2
28.8–
31.7
1.8 
(1.7–
1.9)
p < 0.001 16.9 16.4–17.5
Influenza B NA NA NA NA NA NA 23.4 22.1–24.7
0.5 
(0.5–
0.5)
NA 43.7 42.8–44.6
A(H1N1)pdm09-related 
ICU admissions 1.7
1.4–
2.0
0.8 
(0.6–
1.0)
p = 0.064 2.1 1.9–2.3 1.9 1.6–2.3
2.4 
(1.9–
3.0)
p < 0.001 0.8 0.7–0.9
A(H1N1)pdm09-related 
mortality 0.5
0.4–
0.8
0.9 
(0.6–
1.4)
p = 0.781 0.6 0.5–0.7 0.9 0.7–1.2
8.3 
(5.1–
13.5)
p < 0.001 0.1 0.1–0.2
CI: confidence interval; ICU: intensive care unit; IRR: incidence risk ratio; NA: not available.
a Other countries: Finland, Iceland, Norway and Sweden.
b Reference group: Other countries.
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pdm09 in the 2010/11 season according to a vaccine 
effectiveness study [10]. In Greece, where a 3% popu-
lation pandemic vaccination coverage was reported, 
higher ICU admission rates and higher overall popula-
tion mortality due to influenza A(H1N1)pdm09 was also 
reported in 2010/11 compared with the previous sea-
son [33]. In Ireland, 23% of the population eligible for 
vaccination was vaccinated during the pandemic and 
the number of influenza A(H1N1)pdm09-related ICU 
admissions and deaths increased from the 2009/10 to 
the 2010/11 influenza season [34].
Adjuvanted vaccines have shown to provide longer 
lasting immunity in children, adults and populations 
with chronic conditions compared with non-adjuvanted 
vaccines [8,9,35]. They induce antibodies that show 
higher levels of haemagglutination inhibition and influ-
enza-neutralising activity than non-adjuvanted vac-
cines [36-38]. In addition, the 2009 pandemic vaccine 
strain closely matched the influenza A(H1N1)pdm09 
virus strain that circulated during the season 2010/11. 
Thus, in 2010/11 the population of the Nordic countries 
could have been protected to some extent by the pan-
demic vaccine administered more than one year earlier.
Several national and sub-national studies have reported 
the prevailing effectiveness of the pandemic vaccine in 
2009/10 in preventing influenza A(H1N1)pdm09 dur-
ing season 2010/11. In Sweden, the pandemic vaccine 
effectiveness (VE) was 72% against hospitalisation in 
2010/11 [8]. In Finland, the VE against A(H1N1)pdm09 
influenza was 81% if vaccinated with pandemic vaccine 
and 88% if vaccinated with either pandemic vaccine 
or TIV in 2010/11 [39]. In UK, the VE against A(H1N1)
pdm09 in 2010/11 was 34% if vaccinated with pan-
demic vaccine; 46% if vaccinated with TIV in 2010/11 
and 63% if vaccinated with both [10]. These results are 
in line with our findings of a lower incidence of severe 
influenza outcomes in 2010/11 in the four countries 
with higher pandemic vaccination coverage compared 
with Denmark.
Limitations
Although the five Nordic countries have similar health-
care systems, they may have had different testing prac-
tices for influenza confirmation and subtyping, and 
thus ascertainment of the diagnosis. This would have 
affected the comparability of the data between coun-
tries and between the two seasons. This limitation is 
however minimised due to three facts. Firstly, testing 
recommendations were similar in the five countries 
from the beginning of the pandemic and changed to 
only risk group patients or close contacts of laboratory-
confirmed cases in all countries from week 29 to 32. 
Furthermore, testing bias probably did not affect the 
ICU admission rates, as the testing recommendations 
at hospital level (including ICU units) in all countries 
were to swab all patients hospitalised with influenza 
symptoms or lower airway infection [22-26]. Secondly, 
the proportion of specimens positive for influenza was 
similar among the three countries with available infor-
mation which may additionally indicate that the case 
ascertainment was comparable throughout this period. 
The percentage of positive samples reflects the influ-
enza transmission if systematically sampled e.g. in 
sentinel systems. But different criteria for diagnostic 
swabbing of symptomatic patients (e.g. more severely 
ill patients with higher likelihood of being influenza 
positive) could also have accounted for differences 
in the percentage between countries. Thirdly, the age 
distribution of laboratory-confirmed influenza A(H1N1)
pdm09 and influenza B was similar (Figure 2) between 
the countries in the two seasons which also points 
towards a comparable case ascertainment. In addi-
tion, the testing practices may have changed due to 
different disease awareness during the pandemic and 
the following year. However, there is no evidence that 
changes in disease awareness between the two sea-
sons would have differed markedly between the coun-
tries concerned.
Data on the TIV coverage in the five countries in 
2009/10 and 2010/11 seasons was not included in the 
analysis, as it was not available for all countries. This 
could have influenced the morbidity and mortality due 
to influenza in both seasons, as in Canada, where stud-
ies have shown an increased risk of influenza A(H1N1)
pdm09 in 2009/10 among TIV recipients in 2008/09 
[40]. Therefore, the TIV in 2009/10 and 2010/11 could 
have influenced the morbidity and mortality due to 
influenza in both seasons. However, in the Nordic 
countries the TIV was only offered to the risk groups 
and not to the general population, and it is therefore 
likely to have had a minor impact on the overall inci-
dence of disease. In addition, the coverage in 2010/11 
would only have had an impact on the results if there 
were differences in the risk groups or coverages in the 
other Nordic countries compared with Denmark. This 
is not the case since the seasonal vaccination recom-
mendations were similar in the Nordic countries and 
included the same risk groups, except for the recom-
mendation of vaccinating healthy children in Finland 
[41]. Moreover, vaccination coverages in the season 
Table 4
Timing of recommendations of influenza testing, 
Denmark, Finland, Iceland, Norway and Sweden, 2009/10 
influenza A(H1N1)pdm09 pandemic
Country
Groups recommended for testing and week
Casesa and their 
contacts
Cases at risk of severe disease 
and their contacts
Denmark Week 18 Week 29
Finland Week 18 Week 31
Iceland Week 21 Week 33
Norway Week 18 Week 30
Sweden Week 17 Week 29
a Individuals fulfilling the national case definition for suspected 
case of influenza A(H1N1)pdm09.
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2010/11 were similar in three of the Nordic countries 
in the elderly population: 50% in Denmark, 47% in 
Norway among elderly and risk groups, and 54% in 
Sweden [42].
The optimal design to address a prolonged effect of 
the pandemic vaccine would have been a multi-country 
register-based study with individual level information 
on pandemic and seasonal vaccinations and influenza 
A(H1N1)pdm09 outcomes. If this data had been avail-
able it would have been possible to conduct pandemic 
VE analysis with stratification on previous TIV vaccina-
tion in the two seasons.
Finally, it is a limitation that we only included informa-
tion on vaccination coverage as a predictor of severe 
outcomes of influenza, when influenza transmission is 
known to be influenced by a range of factors other than 
vaccination such as population density, social factors, 
weather conditions and latitude which were not taken 
into account in this study.
Conclusions and recommendations
Our observational study allowed a comprehensive 
description of timing and coverage of the pandemic 
vaccinations and severe outcomes of influenza A(H1N1)
pdm09 during the pandemic and following season in 
the five Nordic countries.
In response to the A(H1N1)pdm09 pandemic, Finland, 
Iceland, Norway and Sweden recommended vac-
cination to the whole population at a certain time of 
the pandemic and reached coverages of 41 to 60%, 
whereas Denmark throughout the pandemic only rec-
ommended to vaccinate risk groups , leading to a cov-
erage of 6% of the population. This difference does not 
seem to have influenced the timing of the epidemic nor 
the disease burden in the 2009/10 pandemic season, 
probably because the vaccines were distributed too 
late relative to the epidemic peak. However, in the fol-
lowing influenza season 2010/11, the four countries 
with higher pandemic vaccination coverage experi-
enced a season dominated by influenza B and had 
less influenza A(H1N1)pdm09-related severe outcomes 
compared with Denmark. Our results indicate that the 
adjuvanted pandemic vaccination may have had an 
impact on influenza type/subtype distribution and 
influenza-related severe outcomes in the season fol-
lowing the pandemic, although other factors may have 
also played a role.
We did not aim to answer the question about the most 
appropriate vaccination strategy during a pandemic. 
However, the study indicates that different vaccination 
strategies may have had consequences for the influ-
enza season following the pandemic season and this 
should be part of an overall assessment of a pandemic 
response. In such an assessment the risk of severe and 
unexpected rare adverse events also needs to be taken 
into consideration when evaluating the risk/benefit of 
a pandemic vaccination campaign.
In order to support the assessment of vaccination 
strategies, we recommend the use of comprehensive 
influenza surveillance systems that, in addition to 
surveillance of influenza intensity and circulating sub-
types, also include severe influenza-related outcomes 
to monitor changes in the impact of influenza between 
seasons across countries. We also recommend to keep 
the same surveillance systems in place in the seasons 
following the pandemic, in order to enable full evalua-
tion of the impact of pandemic vaccination campaigns.
The Nordic influenza comparison group
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